ijms-logo

Journal Browser

Journal Browser

Gynecological Oncology: From Molecular Basis to Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 August 2025 | Viewed by 767

Special Issue Editors


E-Mail Website
Guest Editor
Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, and AGO Study Group, Wiesbaden, Germany
Interests: gynecological oncology

Special Issue Information

Dear Colleagues,

This Special Issue entitled Gynecological Oncology: From Molecular Basis to Therapy delves into the latest advancements in the field of gynecological oncology, spanning from the molecular underpinnings of these diseases to their therapeutic implications. With advancements in biomedical research, our understanding of the molecular mechanisms driving gynecological cancers, such as cervical, ovarian, and endometrial cancers, has significantly deepened, propelling the development of targeted therapies and personalized medicine. Molecular biological insights have paved the way for the development of novel therapeutic strategies that promise to transform the landscape of gynecological cancer treatment. Targeted therapies, immunotherapy, epigenetic modulators, and personalized medicine approaches offer new hope for improving patient outcomes and advancing towards the goal of precision oncology in the management of gynecological malignancies.

The present Special Issue, entitled “Gynecological Oncology: From Molecular Basis to Therapy”, aims to present recent research developments to the wider community involved in this field. This Special Issue welcomes comprehensive reviews and original research articles from leading research institutions worldwide, providing a platform for clinicians, researchers, and students to share the latest scientific findings, clinical experiences, and treatment strategies.

Prof. Dr. Martin Götte
Prof. Dr. Lars Hanker
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological oncology
  • molecular basis
  • targeted therapy
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 3841 KiB  
Article
The Prognostic Value of the Hedgehog Signaling Pathway in Ovarian Cancer
by Noor D. Salman, Lars C. Hanker, Balázs Győrffy, Áron Bartha, Louisa Proppe and Martin Götte
Int. J. Mol. Sci. 2025, 26(12), 5888; https://doi.org/10.3390/ijms26125888 - 19 Jun 2025
Viewed by 416
Abstract
The hedgehog pathway is a major regulator of cell growth and differentiation during embryogenesis and early development. The literature suggests that variations in this pathway’s genes play a role in tumor progression and response to therapy. This study aimed to assess the correlation [...] Read more.
The hedgehog pathway is a major regulator of cell growth and differentiation during embryogenesis and early development. The literature suggests that variations in this pathway’s genes play a role in tumor progression and response to therapy. This study aimed to assess the correlation between the expression levels of selected genes of this pathway and the progression-free and overall survival of ovarian cancer patients. Using the database Kaplan–Meier plotter, which includes the gene expression and survival data of 1565 ovarian cancer patients, higher expression levels of the genes SHH, PTCH1, PTCH2, and GLI1 displayed better survival correlations, while GLI, GLI3, and SUFU correlated with adverse outcomes. Further dissection revealed a differential impact of the genes in specific clinical-histopathological categories. Notably, higher expression levels of SUFU were associated with a negative impact on ovarian cancer patients under many clinical–histopathological aspects. These results shed new light on the role of these genes in the chemoresponsiveness of ovarian cancer, especially SUFU, which could be considered a novel indicator for poor prognosis in epithelial ovarian cancer. Full article
(This article belongs to the Special Issue Gynecological Oncology: From Molecular Basis to Therapy)
Show Figures

Figure 1

Back to TopTop